<DOC>
	<DOCNO>NCT01984983</DOCNO>
	<brief_summary>The Phase I study assess basic safety , tolerability , immunogenicity DNA-based Venezuelan equine encephalitis virus ( VEEV ) vaccine candidate deliver electroporation . The study enroll 40 healthy adult volunteer age 18-49 comprise evaluation intradermal intramuscular administration electroporation . Administration vaccine candidate two DNA dose level ( 0.5 mg/ml 2.0 mg/ml ) route administration . Electroporation administer use TriGrid Delivery System device intramuscular intradermal delivery . An additional group subject serve placebo control , receive injection saline electroporation . The overall goal study determine human clinical study vaccine candidate warrant , , aid selection dose route administration future study .</brief_summary>
	<brief_title>Study DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered Electroporation Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalomyelitis , Equine</mesh_term>
	<mesh_term>Encephalomyelitis , Venezuelan Equine</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy adult male nonpregnant , nonlactating female , age 1849 ( inclusive ) time screen Have provide write informed consent screen Free clinically significant health problem clinical lab abnormality , determine pertinent medical history , lab evaluation , clinical examination entry study Available able participate study visit procedure If sexually active , know least 1 year postmenopausal , willing use effective method contraception ( e.g. , birth control pill , diaphragm , cervical cap , intrauterine device , condom , anatomical sterility [ self partner ] ) date screen least 6 month last injection Negative VEEV IgG antibody test result screening ( ELISA ) History serologic evidence prior infection VEE virus prior participation VEE virus vaccine trial History severe local systemic reaction vaccination history severe allergic reaction History GuillainBarre Syndrome Ongoing participation another clinical trial Receipt plan receipt experimental license vaccine , except license seasonal influenza vaccine , within period 30 day prior initial injection 60 day Day 70 followup . ( ~ 6 month period total ) Receipt plan receipt allergy treatment involve antigen injection within period 30 day prior first injection period 60 day Study Day 70 ( ~6 month period total ) Individuals skinfold measurement cutaneous subcutaneous tissue eligible injection site ( leave right medial deltoid region ) exceed 40 mm Individuals ability observe possible local reaction eligible injection site ( deltoid region ) , opinion investigator , unacceptably obscure due physical condition permanent body art Therapeutic traumatic metal implant skin muscle either deltoid region . Acute chronic , clinically significant hematologic , pulmonary , cardiovascular , hepatic renal functional abnormality determine investigator base medical history , physical examination , EKG , and/or laboratory screen test Pregnant lactate female , female intend become pregnant study period Administration immunoglobulins and/or blood product within 120 day precede study entry plan administration study period Any confirm suspected immunosuppressive immunodeficient condition , include HIV infection Administration chronic ( defined 14 day ) immunosuppressant 's immunemodifying drug within 6 month study entry For corticosteroid , mean prednisone , equivalent , great equal 0.5 mg/kg/day ; Inhaled topical steroid allow Any chronic active neurologic disorder , include seizure epilepsy , exclude single febrile seizure child Syncopal episode within 12 month screen Suspected known current alcohol abuse define American Psychiatric Association DSM IV ( Diagnostic Statistical Manual Mental Disorders4th edition ) Chronic active illicit and/or intravenous drug use history Unwilling allow storage use blood future alphavirusrelated research Any significant finding opinion investigator would increase risk individual adverse outcome participating study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Venezuelan equine encephalitis virus</keyword>
	<keyword>DNA vaccine</keyword>
	<keyword>electroporation</keyword>
	<keyword>intradermal</keyword>
	<keyword>intramuscular</keyword>
</DOC>